CA3020792A1 - Conjugates comprising ripk2 inhibitors - Google Patents

Conjugates comprising ripk2 inhibitors Download PDF

Info

Publication number
CA3020792A1
CA3020792A1 CA3020792A CA3020792A CA3020792A1 CA 3020792 A1 CA3020792 A1 CA 3020792A1 CA 3020792 A CA3020792 A CA 3020792A CA 3020792 A CA3020792 A CA 3020792A CA 3020792 A1 CA3020792 A1 CA 3020792A1
Authority
CA
Canada
Prior art keywords
tert
dimethyl
methylpiperazin
pyrazol
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3020792A
Other languages
English (en)
French (fr)
Inventor
Linda N. Casillas
John David Harling
Afjal Hussain MIAH
Ian Edward David Smith
Mark David RACKHAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CA3020792A1 publication Critical patent/CA3020792A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3020792A 2016-04-20 2017-04-18 Conjugates comprising ripk2 inhibitors Abandoned CA3020792A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324944P 2016-04-20 2016-04-20
US62/324,944 2016-04-20
PCT/EP2017/059090 WO2017182418A1 (en) 2016-04-20 2017-04-18 Conjugates comprising ripk2 inhibitors

Publications (1)

Publication Number Publication Date
CA3020792A1 true CA3020792A1 (en) 2017-10-26

Family

ID=58548715

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3020792A Abandoned CA3020792A1 (en) 2016-04-20 2017-04-18 Conjugates comprising ripk2 inhibitors

Country Status (10)

Country Link
US (1) US10781205B2 (enExample)
EP (1) EP3445759A1 (enExample)
JP (1) JP2019514878A (enExample)
KR (1) KR20180135038A (enExample)
CN (1) CN109311867A (enExample)
AU (1) AU2017253560B2 (enExample)
BR (1) BR112018071408A2 (enExample)
CA (1) CA3020792A1 (enExample)
RU (1) RU2018134981A (enExample)
WO (1) WO2017182418A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506872D0 (en) * 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
CN110087680B (zh) 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
CA3103185A1 (en) * 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
CN112638905A (zh) * 2018-08-28 2021-04-09 南京明德新药研发有限公司 作为rip2激酶抑制剂的喹唑啉类衍生物
KR20210141554A (ko) 2019-03-21 2021-11-23 코디악 바이오사이언시즈, 인크. 세포외 소포 접합체 및 이의 용도
EP3941607A1 (en) 2019-03-21 2022-01-26 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
JP7764027B2 (ja) 2019-07-31 2025-11-05 ファイメクス株式会社 複素環化合物
JP2021024787A (ja) 2019-07-31 2021-02-22 ファイメクス株式会社 複素環化合物
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
TW202221000A (zh) 2020-09-30 2022-06-01 英屬開曼群島商百濟神州有限公司 用於降解ｅｇｆｒ之雙功能化合物及相關使用方法
CN116847848A (zh) 2021-02-10 2023-10-03 百济神州有限公司 Egfr降解剂和使用方法
CN114014890A (zh) * 2021-03-12 2022-02-08 爱科诺生物医药(香港)有限公司 具有rip2激酶抑制活性的化合物，包含其的药物组合物，及其应用
EP4330251A4 (en) 2021-04-30 2025-03-05 BeiGene Switzerland GmbH EGFR DEGRADING AGENTS AND METHODS OF USE THEREOF
CA3240051A1 (en) 2021-12-30 2023-07-06 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
EP4578856A4 (en) * 2022-09-30 2026-07-29 Ubience Inc HETEROCYCLIC COMPOUND
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
WO2024246838A1 (en) 2023-05-31 2024-12-05 Beigene Switzerland Gmbh Compounds for the degradation of egfr kinase
WO2025092821A1 (zh) * 2023-11-01 2025-05-08 成都赜灵生物医药科技有限公司 喹唑啉衍生物类ripk2抑制剂及其用途
CN122270449A (zh) 2023-12-13 2026-06-23 百济神州(苏州)生物科技有限公司 通过将irak4抑制剂与e3连接酶配体缀合来降解irak4以及使用方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2008128171A2 (en) 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
EP2296650B1 (en) * 2008-05-16 2020-05-06 Novartis AG Immunomodulation by iap inhibitors
MX351274B (es) 2009-08-12 2017-10-06 Novartis Ag Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis.
JP2013526484A (ja) 2010-05-07 2013-06-24 グラクソ グループ リミテッド キナーゼ阻害剤としてのアミノ‐キノリン
UY33549A (es) 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
JP6026441B2 (ja) * 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのアミノキノリン
GB201106817D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
TWI547494B (zh) * 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
AU2013306087B2 (en) 2012-08-23 2017-08-10 The Regents Of The University Of Michigan Bivalent inhibitors of IAP proteins and therapeutic methods using the same
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
US9603889B2 (en) 2012-10-02 2017-03-28 Bristol-Myers Squibb Company IAP antagonists
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN104854100B (zh) 2012-12-11 2017-05-24 霍夫曼-拉罗奇有限公司 二聚化合物
KR101335240B1 (ko) 2012-12-13 2013-11-29 전호건 수평 연속 방식의 탄화장치
CN105143208B (zh) * 2013-02-21 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的喹唑啉
GB201311888D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
CN115368356B (zh) 2013-12-20 2025-05-09 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
GB201506871D0 (en) * 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201506872D0 (en) * 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds

Also Published As

Publication number Publication date
WO2017182418A1 (en) 2017-10-26
JP2019514878A (ja) 2019-06-06
CN109311867A (zh) 2019-02-05
US20190119271A1 (en) 2019-04-25
RU2018134981A (ru) 2020-05-20
AU2017253560B2 (en) 2019-03-21
BR112018071408A2 (pt) 2019-02-05
EP3445759A1 (en) 2019-02-27
AU2017253560A1 (en) 2018-11-08
KR20180135038A (ko) 2018-12-19
US10781205B2 (en) 2020-09-22

Similar Documents

Publication Publication Date Title
AU2017253560B2 (en) Conjugates comprising RIPK2 inhibitors
AU2016252404B2 (en) Novel compounds
CN112778276B (zh) 作为shp2抑制剂的化合物及其应用
CA2926207C (en) Heteroaryl compounds as btk inhibitors and uses thereof
DK3050882T3 (en) PIPERIDIN-4-YL-AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
CA2947338C (en) Multi-fluoro-substituted compound as bruton's tyrosine kinase (btk) inhibitor
RU2677884C2 (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
US8633206B2 (en) Pyrrolo[2,3-D]pyrimidine compounds
JP6166845B2 (ja) ２，６−置換プリン誘導体および増殖性障害の治療におけるそれらの使用
CA3070171A1 (en) Tlr7/8 antagonists and uses thereof
CA3005766A1 (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
CA2978170A1 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
HUE033587T2 (hu) Bipirazol-származékok mint JAK inhibitorok
CN116348469B (zh) 一种高活性Wnt通路抑制剂化合物
CA2846187A1 (en) Pyrimido-pyridazinone compounds and use thereof
EP4562007A1 (en) Targeted protein degradation of parp14 for use in therapy
HK30089210A2 (en) A highly active wnt pathway inhibitor compound
HK1230164B (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20221019